Wall Street Zen upgraded shares of NextPlat (NASDAQ:NXPL – Free Report) to a hold rating in a research report sent to investors on Saturday.
A number of other brokerages have also recently commented on NXPL. Litchfield Hills Research began coverage on NextPlat in a research report on Wednesday, June 24th. They set a “buy” rating and a $11.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of NextPlat in a research note on Friday, August 7th. Finally, Zacks Research raised NextPlat to a “hold” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.00.
Get Our Latest Stock Report on NXPL
NextPlat Trading Down 0.2%
NextPlat (NASDAQ:NXPL – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.16. NextPlat had a negative net margin of 20.38% and a negative return on equity of 54.66%. The business had revenue of $11.88 million during the quarter, compared to the consensus estimate of $11.00 million. Analysts predict that NextPlat will post -0.85 EPS for the current year.
Institutional Investors Weigh In On NextPlat
An institutional investor recently bought a new stake in NextPlat stock. Citadel Advisors LLC purchased a new position in shares of NextPlat Corp. (NASDAQ:NXPL – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned 0.19% of NextPlat as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.30% of the company’s stock.
About NextPlat
NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.
Featured Articles
- Five stocks we like better than NextPlat
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for NextPlat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextPlat and related companies with MarketBeat.com's FREE daily email newsletter.
